<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679287</url>
  </required_header>
  <id_info>
    <org_study_id>18617</org_study_id>
    <secondary_id>R01DK085623</secondary_id>
    <nct_id>NCT02679287</nct_id>
  </id_info>
  <brief_title>Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control</brief_title>
  <official_title>Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostic Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TypeZero Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use an investigational type of technology called Closed-Loop
      Control (CLC) Medical Platform System to help control blood sugar in people with type 1
      diabetes mellitus in a home setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CLC is an &quot;artificial pancreas&quot; (AP) application that uses advanced closed loop control
      algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The
      system modulates insulin to keep blood glucose in a targeted range. The CLC will be deployed
      with different functionalities at different stages of the trial, resulting in variation in
      what the subject will be responsible for and what the system will drive.These functionalities
      occur in a randomized cross-over design, each occurring for 8 weeks. These modalities are:

        1. SAP=sensor-augmented pump only

        2. USS+SAP (d)= SAP during day and CLC starting at dinner and continuing overnight

        3. USS+CLC (d)= 24-hour Day and Night Closed Loop Control
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time &lt;70 mg/dl by CGM and Hemoglobin A1c</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overnight CLC achieved by USS+SAP(d) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs â‰¥7.5% and time of day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time between 70-180 mg/dL by CGM</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time &gt;180 mg/dL by CGM</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose by CGM (overall, 7am and bedtime)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Blood Glucose Index (LBGI)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Blood Glucose Index (HBGI)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLC</intervention_name>
    <description>The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Closed Loop Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes for at least one year

          -  using insulin for at least 1 year

          -  an insulin pump for at least 6 months

          -  willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine
             (Apidra).

        Exclusion Criteria:

          -  a medical condition or being been treated with medications that might interfere with
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue A. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UVA Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sue A. Brown, MD</last_name>
    <phone>434-982-0602</phone>
    <email>SAB2F@VIRGINIA.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura L. Kollar, RN</last_name>
    <phone>434-982-6479</phone>
    <email>LLK7M@VIRGINIA.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura M. Kollar, RN</last_name>
      <phone>434-982-6479</phone>
      <email>llk7m@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sue M. Brown, MD</last_name>
      <phone>434-982-0602</phone>
      <email>sab2f@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stacey M. Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris P. Kovatchev, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda G. Fredrick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaclyn Shepard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Sue Brown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Closed-Loop Control (CLC)</keyword>
  <keyword>Sensor-Augmented Therapy (SAP)</keyword>
  <keyword>USS Virginia</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>Artificial Pancreas (AP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

